# BPC-157 + TB-500 – 10mg/vial (5mg BPC-157 + 5mg TB-500)

**Independent lab result · batch PTW-BPCTB10-2608-001**

BPC-157 + TB-500 (labelled 5 mg + 5 mg). Tested by Janoshik Analytical (task #243312), analysis conducted 23 Oct 2026. The sample was pulled from our own stock, submitted and paid for by Portal to Wellness, and the report names us as the client.

- BPC-157: 4.45 mg per vial, labelled 5 mg
- TB-500 (TB4): 4.42 mg per vial, labelled 5 mg
- **This batch measured about 11% below its labelled amount** (8.87 mg in total against 10 mg labelled; the laboratory tested the sample twice). We are selling it with these exact figures published while we raise the result with our supplier. Blend tests confirm identity and amount; they do not give a purity percentage.

[View and verify the full report on Janoshik’s site →](https://verify.janoshik.com/tests/243312-BPC157TB500_10mg_8UHFGAPNUUAE)

This result applies to batch PTW-BPCTB10-2608-001. The batch number is printed on the vial label. See all published results on our [Lab Testing & Verification](https://portaltowellness.net/lab-verification-quality-testing/) page.

### BPC-157, TB-500 & GHK-Cu: What’s the Difference?

Six related products, in two formats. Here’s what’s actually in each one.

| Product | Contains | Format | Price |
| --- | --- | --- | --- |
| BPC-157 (injectable) | BPC-157 only | Injectable vial, 10mg | $56.00 |
| BPC-157 (capsules) | BPC-157 only | 100 capsules, 500mcg each | $155.00 |
| TB-500 | TB-500 only | Injectable vial, 10mg | $72.00 |
| BPC-157 + TB-500 | BPC-157 + TB-500 (5mg + 5mg) | Injectable vial, 10mg total | $69.00 |
| BPC + TB Capsules | BPC-157 + TB-500 (500mcg + 500mcg) | 100 capsules, 1,000mcg total each | $94.05 |
| GLOW-70 | GHK-Cu + TB-500 + BPC-157 (50mg + 10mg + 10mg) | Injectable vial | $112.00 |

**GLOW-70 vs. standalone GHK-Cu – the question we get most:** GHK-Cu (sold on its own as a 100mg vial, $49.00) is a single copper-binding peptide. GLOW-70 is a different, separate product: a blended vial that combines GHK-Cu with two other peptides, TB-500 and BPC-157, in one injection (50mg + 10mg + 10mg). If you’re comparing the two, the real question is single-compound vs. a three-compound blend – GLOW-70 is not just “more GHK-Cu,” it’s GHK-Cu plus two additional peptides in the same vial.

Backed by the Research [Read: BPC-157 and TB-500: Preclinical Literature Compared →](https://portaltowellness.net/research/the-recovery-stack-how-bpc-157-and-tb-500-work-together/)

### Overview

This combination research vial provides equal quantities of BPC-157 (Body Protection Compound-157) and TB-500 (Thymosin Beta-4 fragment) in a single lyophilized preparation supplied as a lyophilized powder. Both components carry extensive independent preclinical research bases across gastrointestinal biology, musculoskeletal repair, and tissue remodeling.

### What It Is

This vial provides 5mg BPC-157 (15-aa synthetic peptide, MW ~1,419 Da, CAS 137525-51-0) and 5mg [TB-500](https://portaltowellness.net/tb-500-thymosin-beta-4-research-overview/) (17-aa Thymosin Beta-4 fragment, MW ~2,024 Da, CAS 77591-33-4), co-lyophilized for a total of 10mg per vial.

### Key Research Applications

- Combined musculoskeletal tissue repair research in tendon, ligament, and muscle models
- Gastrointestinal mucosal repair and systemic tissue repair endpoint combination studies
- Angiogenesis and wound healing multi-mechanism marker studies
- Parenteral administration route research (SC, IP) using co-formulated preparations
- Dose-response combination studies examining additive vs. independent mechanism endpoints
- NF-kB, inflammatory cytokine, and anti-inflammatory pathway studies using combined administration
- Cardiac and vascular tissue repair combination research models

### Technical Specifications

| BPC-157 Content | 5mg (MW ~1,419 Da, CAS 137525-51-0) |
| --- | --- |
| TB-500 Content | 5mg (MW ~2,024 Da, CAS 77591-33-4) |
| Total Vial Content | 10mg (co-lyophilized) |
| Purity | Supplier specification: ≥98% per component. Our Janoshik test of batch PTW-BPCTB10-2608-001 measured 4.45 mg BPC-157 and 4.42 mg TB-500 per vial; blend tests do not report purity |
| Form | Lyophilized powder (injectable grade) |
| Storage | −4 °F long-term |

**FOR RESEARCH USE ONLY.** Not intended for human or veterinary consumption, medical diagnosis, treatment, or prevention of any disease or condition. This product has not been evaluated by the FDA or any regulatory agency. Must be handled by qualified research personnel in a compliant laboratory setting. These statements have not been evaluated by the Food and Drug Administration.

Not sure which compounds fit your research? [Browse the Research Hub →](https://portaltowellness.net/research/)

### Related research (educational)

- [Overlapping Pathways in Circadian, Repair and Mitochondrial Biology](https://portaltowellness.net/research/sleep-repair-energy-one-system/)
- [BPC-157 and TB-500: Preclinical Literature Compared](https://portaltowellness.net/research/the-recovery-stack-how-bpc-157-and-tb-500-work-together/)
- [Recovery & Repair Research Compounds: A Complete Guide](https://portaltowellness.net/research/recovery-repair-research-compounds-guide/)

Regulatory Status Note

On July 23–24, 2026, FDA’s Pharmacy Compounding Advisory Committee reviewed whether BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, and emideltide (DSIP) should be added to the 503A Bulks List for pharmacy compounding. The committee voted to recommend six of the seven; emideltide (DSIP) was **not** recommended. FDA’s own briefing documents had recommended against all seven.

A committee vote is a recommendation only. It does not constitute FDA approval, does not establish safety or effectiveness, and does not change the status of this product, which is sold strictly for research use. FDA must complete formal rulemaking before any substance is added to the list. [Source: FDA Advisory Committee Calendar](https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026) . Last reviewed: August 17, 2026.

At a Glance: Four Separate Questions

- **Research status:** Sold for research/laboratory use only, not as a consumer drug.
- **Compounding status:** An FDA advisory committee recommended possible inclusion on the 503A Bulks List (non-binding). FDA has not issued a final decision.
- **FDA approval status:** Not FDA-approved for any use.
- **Evidence status:** Preclinical/animal research on tissue repair for both peptides; no completed human clinical trials have established safety or efficacy for either compound.

Last reviewed: August 9, 2026 — status unchanged (still an advisory committee recommendation; not final 503A inclusion or FDA approval). See our [full explainer on these four categories](https://portaltowellness.net/research/compounded-peptide-vs-research-peptide/) .

Research Library

- [BPC-157, TB-500 and MOTS-c: Inside the FDA’s July 2026 Compounding Review](https://portaltowellness.net/research/fda-peptide-review-july-2026/)
- [FDA PCAC July 2026: BPC-157, TB-500, and MOTS-c Under Official Review](https://portaltowellness.net/research/fda-peptide-review-july-2026/)
- [BPC-157, TB-500, and MOTS-c Under FDA Advisory Review: What Researchers Need to Know](https://portaltowellness.net/research/fda-peptide-review-july-2026/)
- [FDA’s July 2026 503A Review: What It Means for BPC-157, TB-500, and MOTS-c Researchers](https://portaltowellness.net/research/fda-peptide-review-july-2026/)
- [What the July 2026 FDA Compounding Advisory Committee Means for Peptide Researchers](https://portaltowellness.net/research/fda-peptide-review-july-2026/)

**Update — July 24, 2026:** On July 23, the committee voted. BPC-157, KPV, and TB-500 each passed 8-6 with one abstention; MOTS-c passed 7-5 with two abstentions. The recommendation is non-binding — FDA is not required to follow it, must still issue a formal decision, and the process may require additional rulemaking before any compounding pharmacy could act on it. No peptide has been FDA-approved, and this update does not constitute or imply a therapeutic claim. [Source: STAT News](https://www.statnews.com/2026/07/23/fda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv/)

**Prefer a single compound?** The [BPC-157 10mg vial](https://portaltowellness.net/shop/bpc-157-10mg-vial/) supplies BPC-157 on its own, for research designs that need one variable rather than a blend.

**All BPC-157 formats in one place.** Compare injectable vials, oral capsules and blend preparations — presentation, pricing and current lab testing status — on the [BPC-157 product index](https://portaltowellness.net/bpc-157/) . Research use only.

---

Source: https://portaltowellness.net/shop/bpc-157-tb-500-injectable/
Research use only. Terms: https://portaltowellness.net/research-use-only/